3308. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
Miao-Zhen Qiu 1, Do-Youn Oh 2, Ken Kato 3, Tobias Arkenau 4, Josep Tabernero 5, Marcia Cruz Correa 6, Anastasia V Zimina 7, Yuxian Bai 8, Jianhua Shi 9, Keun-Wook Lee 10, Jufeng Wang 11, Elena Poddubskaya 12, Hongming Pan 13, Sun Young Rha 14, Ruixing Zhang 15, Hidekazu Hirano 16, David Spigel 17, Kensei Yamaguchi 18, Yee Chao 19, Lucjan Wyrwicz 20, Umut Disel 21, Roberto Pazo Cid 22, Lorenzo Fornaro 23, Ludovic Evesque 24, Hongwei Wang 25, Yaling Xu 26, Jiang Li 25, Tao Sheng 25, Silu Yang 27,
BMJ. 2024 May 28:385:e078876.
Link